Pharmacoeconomics and Policy2026，Vol.2Issue(2)：P.55-59,5.DOI:10.1016/j.pharp.2026.06.005
Anticipating a regional shift:Preparing the pharmaceutical industry for real-world evidence requirements across East Asia analogous to a Conditional Reimbursement List framework
Hong Li 1Dimitrios Tsourougiannis 2David Bin-Chia Wu 3Chee-Jen Chang4
作者信息
- 1. Department of Pharmacy Practice and Administrative Sciences,James L.Winkle College of Pharmacy,University of Cincinnati,Cincinnati,OH,45267,USA
- 2. Shionogi Pharmaceuticals,Osaka,530-0011,Japan
- 3. Saw Swee Hock School of Public Health,National University of Singapore,Singapore,117549,Singapore School of Pharmacy,Faculty of Health&Medical Sciences,Taylor’s University,Subang Jaya,47500,Malaysia
- 4. Department of Biomedical Sciences,College of Medicine,Chang Gung University,Taoyuan,33302,Taiwan,China Graduate Institute of Health Data Science,College of Intelligent Computing,Chang Gung University,Taoyuan,33302,Taiwan,China Research Service Center for Health Information,Chang Gung University,Taoyuan,33302,Taiwan,China
- 折叠
摘要
关键词
East Asia/regional shift/precision oncology treatments/cellular therapies/pharmaceutical industry/real world evidence/conditional reimbursement/high cost specialty medicines分类
医药卫生引用本文复制引用
Hong Li,Dimitrios Tsourougiannis,David Bin-Chia Wu,Chee-Jen Chang..Anticipating a regional shift:Preparing the pharmaceutical industry for real-world evidence requirements across East Asia analogous to a Conditional Reimbursement List framework[J].Pharmacoeconomics and Policy,2026,2(2):P.55-59,5.
